The European Cystic Fibrosis Society (ECFS) and Cystic Fibrosis Europe (CFE) have jointly submitted a request to the European Medicines Agency (EMA) to expand the approval of Kaftrio® (elexacaftor/tezacaftor/ivacaftor) for individuals with cystic fibrosis (CF) who have non-F508del CFTR variants. You can read the full letter here: ECFS-CFE_LetterCHMP re ETI_120225 Cystic fibrosis, a genetic disorder […]